GeparDouze - 1000th patient randomized!
07.11.2020
NSABP and GBG are pleased to announce the 1000th patient has been randomized for the GeparDouze trial.
On November 5th site 9008, Bon Secours, randomized the 1000th patient to the trial. Congratulations to Site 9008 Bon Secours, Dr. William Irvin, Principal Investigator at the site, and Mary Kate Williams and Melissa Godsey on helping us accomplish this milestone!
As of November 5th there are 1001 patients randomized to the trial. This is an amazing milestone that we could not have reached without our dedicated investigators and research staff at all the sites.
Thank you for ongoing support of the B-59/GBG-96 trial!
News
-
21.09.2023 New review on Immune Cell Infiltration published
A review from the International Immuno-Oncology Biomarker Working about tumor immunology was published in the journal of pathology.
Mehr ... -
07.09.2023 Save the date! GBG Annual Scientific Meeting 2024
Das 21. Annual Scientific Meeting 2024 wird am 29.2. bis 1.3. in Frankfurt stattfinden.
Mehr ... -
05.05.2023 GBG Research at ESMO-BC 2023
GBG Research at ESMO-Breast Cancer Conference 2023 in Berlin
Mehr ... -
28.02.2023 Annual Scientific Report 2022 published
Our Annual Scientific Report 2022 provides a concise overview of current study findings along with important lectures and research posters presented by our members from the last year.
Mehr ... -
24.01.2023 Save the date: 20th GBG Annual Meeting 2023
The 20th GBG Annual Meeting 2023 will start 2nd to 3rd of March 2023 at the Steigenberger Airport Hotel
Mehr ...